Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ertugliflozin to Reduce Arrhythmic Burden in Implantable Cardioverter-defibrillators (ICD)/Cardiac Resynchronisation Therapy(CRT) patientS (ERASe-Trial) - a Phase III Study

NCT04600921 is registered in ClinicalTrials.gov with Medical University of Graz as lead sponsor.

NCT NCT04600921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04600921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ertugliflozin to Reduce Arrhythmic Burden in Implantable Cardioverter-defibrillators (ICD)/Cardiac Resynchronisation Therapy(CRT) patientS (ERASe-Trial) - a Phase III Study
Lead sponsor
Medical University of Graz
Phase
Phase 3
Overall status
Terminated
Start date
June 24, 2021
Completion date
October 18, 2023
Enrollment
55 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

cardiac resynchronization therapy, heart failure with mid range ejection fraction, heart failure with reduced ejection fraction, implantable cardioverter-defibrillators